Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus

Journal of Immunology

Volumn 174, Issue 8, 2005, Pages 4559-4566

  Krebs, Philippe ^a,b   Scandella, Elke ^a   Odermatt, Bernhard ^c   Ludewig, Burkhard ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BETA GALACTOSIDASE; CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TETRAMER;

ADENOVIRUS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; IMMUNIZATION; LIVER; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; TRANSGENIC MOUSE; TUMOR; VIRUS RECOMBINANT;

EID: 17044387019     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.8.4559     Document Type: Article

References (55)

1. Thomas, C. E., A. Ehrhardt, and M. A. Kay. 2003. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4:346.
2. Zhang, Y., N. Chirmule, G. P. Gao, R. Qian, M. Croyle, B. Joshi, J. Tazelaar, and J. M. Wilson. 2001. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3:697.
3. Ziegler, R. J., C. Li, M. Cherry, Y. Zhu, D. Hempel, N. van Rooijen, Y. A. Ioannou, R. J. Desnick, M. A. Goldberg, N. S. Yew, and S. H. Cheng. 2002. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum. Gene Ther. 13:935.
4. Tripathy, S. K., E. Goldwasser, M. M. Lu, E. Barr, and J. M. Leiden. 1994. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc. Natl. Acad. Sci. USA 91:11557.
5. Gomez-Roman, V. R., and M. Robert-Guroff. 2003. Adenoviruses as vectors for HIV vaccines. AIDS Rev. 5:178.
6. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331.
7. + T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J. Immunol. 171:6774.
8. Meng, W. S., L. H. Butterfield, A. Ribas, V. B. Dissette, J. B. Heller, G. A. Miranda, J. A. Glaspy, W. H. McBride, and J. S. Economou. 2001. α-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res. 61:8782.
9. + T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine 21:4555.
10. Tritel, M., A. M. Stoddard, B. J. Flynn, P. A. Darrah, C. Y. Wu, U. Wille, J. A. Shah, Y. Huang, L. Xu, M. R. Betts, et al. 2003. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J. Immunol. 171:2538.
11. Bruna-Romero, O., G. Gonzalez-Aseguinolaza, J. C. Hafalla, M. Tsuji, and R. S. Nussenzweig. 2001. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl. Acad. Sci. USA 98:11491.
12. Prasad, S. A., C. C. Norbury, W. Chen, J. R. Bennink, and J. W. Yewdell. 2001. Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J. Immunol. 166:4809.
13. Kuball, J., M. Schuler, F. E. Antunes, W. Herr, M. Neumann, L. Obenauer-Kutner, L. Westreich, C. Huber, T. Wolfel, and M. Theobald. 2002. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther. 9:833.
14. Fields, P. A., E. Armstrong, J. N. Hagstrom, V. R. Arruda, M. L. Murphy, J. P. Farrell, K. A. High, and R. W. Herzog. 2001. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Ther. 8:354.
15. + T-cell responses during microbial infection. Curr. Opin. Immunol. 15:436.
16. Wold, W. S., K. Doronin, K. Toth, M. Kuppuswamy, D. L. Lichtenstein, and A. E. Tollefson. 1999. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr. Opin. Immunol. 11:380.
17. Zinkernagel, R. M., and H. Hengartner. 2001. Regulation of the immune response by antigen. Science 293:251.
18. Moskophidis, D., F. Lechner, H. Pircher, and R. M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758.
19. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:2205.
20. Wherry, E. J., J. N. Blattman, K. Murali-Krishna, M. R. van der, and R. Ahmed. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77:4911.
21. ++ HIV-specific T cells during progression to AIDS. Blood 99:2505.
22. Lechner, F., D. K. Wong, P. R. Dunbar, R. Chapman, R. T. Chung, P. Dohrenwend, G. Robbins, R. Phillips, P. Klenerman, and B. D. Walker. 2000. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191:1499.
23. + T cell memory in response to low, high, and excessive levels of epitope. J. Immunol. 168:4455.
24. Aichele, P., K. Brduscha-Riem, R. M. Zinkernagel, H. Hengartner, and H. Pircher. 1995. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182:261.
25. Toes, R. E., R. J. Blom, R. Offringa, W. M. Kast, and C. J. Melief. 1996. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156:3911.
26. Weijzen, S., S. C. Meredith, M. P. Velders, A. G. Elmishad, H. Schreiber, and W. M. Kast. 2001. Pharmacokinetic differences between a T cell-tolerizing and a t cell-activating peptide. J. Immunol. 166:7151.
27. Moessler, H., M. Mericskay, Z. Li, S. Nagl, D. Paulin, and J. V. Small. 1996. The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. Development 122:2415.
28. Ookka, M., M. Cohen-Tannoudji, Y. Tanaka, C. Babinet, and K. Kosmatopoulos. 1996. Medullary thymic epithelial cells induce tolerance to intracellular proteins. J. Immunol. 156:968.
29. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.
30. Ludewig, B., S. Ehl, U. Karrer, B. Odermatt, H. Hengartner, and R. M. Zinkernagel. 1998. Dendritic cells efficiently induce protective antiviral immunity. J. Virol. 72:3812.
31. Junt, T., H. Nakano, T. Dumrese, T. Kakiuchi, B. Odermatt, R. M. Zinkernagel, H. Hengartner, and B. Ludewig. 2002. Antiviral immune responses in the absence of organized lymphoid T cell zones in plt/plt mice. J. Immunol. 168:6032.
32. + T cells in vivo: implications for adaptive immunotherapy. Eur. J. Immunol. 31:1772.
33. Ludewig, B., A. F. Ochsenbein, B. Odermatt, D. Paulin, H. Hengartner, and R. M. Zinkernagel. 2000. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. 191:795.
34. Burgert, H. G., Z. Ruzsics, S. Obermeier, A. Hilgendorf, M. Windheim, and A. Elsing. 2002. Subversion of host defense mechanisms by adenoviruses. Curr. Top. Microbiol. Immunol. 269:273.
35. Selin, L. K., and R. M. Welsh. 2004. Plasticity of T cell memory responses to viruses. Immunity 20:5.
36. + T-cell response following adenovirus vaccination. J. Virol. 77:13407.
37. Kagi, D., B. Ledermann, K. Burki, R. M. Zinkernagel, and H. Hengartner. 1995. Lymphocyte-mediated cytotoxicity in vitro and in vivo: mechanisms and significance. Immunol. Rev. 146:95.
38. Guidotti, L. G., P. Borrow, A. Brown, H. McClary, R. Koch, and F. V. Chisari. 1999. Noncytopathtc clearance of lymphocytic choriomeningitis virus from the hepatocyte. J. Exp. Med. 189:1555.
39. + T cells in vivo. Eur. J. Immunol. 30:1356.
40. Steinman, R. M., and M. C. Nussenzweig. 2002. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99:351.
41. + T cells. J. Exp. Med. 186:239.
42. Kurts, C., M. Cannarile, I. Klebba, and T. Brocker. 2001. Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J. Immunol. 166:1439.
43. + T cell tolerance to peripherally expressed antigens. J. Immunol. 163:723.
44. Kurts, C., R. M. Sutherland, G. Davey, M. Li, A. M. Lew, E. Blanas, F. R. Carbone, J. F. Miller, and W. R. Heath. 1999. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA 96:12703.
45. Ohashi, P. S., S. Oehen, K. Buerki, H. Pircher, C. T. Ohashi, B. Odermatt, B. Malissen, R. M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305.
46. + T cells undergo peripheral tolerance. Immunity 17:73.
47. Zaiss, A. K., Q. Liu, G. P. Bowen, N. C. Wong, J. S. Bartlett, and D. A. Muruve. 2002. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76:4580.
48. Arai, K., Z. X. Liu, T. Lane, and G. Dennert. 2002. IP-10 and Mig facilitate accumulation of T cells in the virus-infected liver. Cell Immunol. 219:48.
49. + T cells by the normal liver. J. Immunol. 163:3202.
50. Crispe, I. N., T. Dao, K. Klugewitz, W. Z. Mehal, and D. P. Metz. 2000. The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol. Rev. 174:47.
51. Rea, D., M. J. Havenga, M. van Den Assem, R. P. Sutmuller, A. Lemckert, R. C. Hoeben, A. Bout, C. J. Melief, and R. Offringa. 2001. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 166:5236.
52. Korokhov, N., G. Mikheeva, A. Krendelshchikov, N. Belousova, V. Simonenko, V. Krendelshchikova, A. Pereboev, A. Kotov, O. Kotova, P. L. Triozzi, et al. 2003. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J. Virol. 77:12931.
53. de Gruijl, T. D., S. A. Luykx-de Bakker, B. W. Tillman, A. J. van den Eertwegh, J. Buter, S. M. Lougheed, G. J. van der Bij, A. M. Safer, H. J. Haisma, D. T. Curiel, et al. 2002. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J. Immunol. 169:5322.
54. Nakamura, M., M. Iwahashi, M. Nakamori, K. Ueda, I. Matsuura, K. Noguchi, and H. Yamaue. 2002. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clin. Cancer Res. 8:2742.
55. Liu, Y., H. Huang, Z. Chen, L. Zong, and J. Xiang. 2003. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. J. Gene Med. 5:668.